Researchers from the universities of Zurich, Yale and Harvard reveal the differences between the characteristics of the ...

For patients with metastatic renal cell carcinoma (mRCC) and progression during or after one to two prior lines of therapy, ...

Disease-free survival is significantly longer with adjuvant pembrolizumab than observation among patients with high-risk ...

FDA approves Lilly's eczema drug, Ebglyss, and the expanded use of Novartis' Kisqali, Merck's Keytruda and AstraZeneca's Fasenra.

The European Society for Medical Oncology’s annual meeting this week featured the hottest emergent areas of cancer ...

Pfizer Inc (NYSE: PFE) presented positive trial data for experimental drug designed for patients suffering from cancer ...

Mirvetuximab soravtansine was the first ADC to show efficacy as a therapy for platinum-resistant ovarian cancer. Despite high ...

The highly anticipated 2024 European Society for Medical Oncology (ESMO) Annual Congress has taken place from September 13 to ...

Oncologists are perturbed by the increase in early-onset tumors and the potential role of lifestyle, though this may not ...

Neoadjuvant therapy is an essential part of high-risk stage III resectable melanoma management, with combination ...

Data from the HERCULES trial presented at the ECTRIMS conference in Copenhagen, Denmark, today showed that tolebrutinib was ...

NEW YORK, Sept. 20, 2024 /PRNewswire/ -- With thousands of press releases published each week, it can be difficult to keep up ...